EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Autoimmune Movement Disorders Complicating Treatment with Immune Checkpoint Inhibitors

Alessandro Dinoto iD, Milena Trentinaglia, Sara Carta, Elisa Mantovani, Sergio Ferrari, Stefano Tamburin iD, Michele Tinazzi iD, Sara Mariotto iD

Movement Disorders Clinical Practice · 2024

DOI: 10.1002/mdc3.14003 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Movement Disorders Clinical Practice, 2024. Verfasst von Alessandro Dinoto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Movement Disorders. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICI) may trigger autoimmune neurological conditions, including movement disorders (MD).

Objectives

The aim of this study was to characterize MDs occurring as immune‐related adverse events (irAEs) of ICIs.

Methods

A systematic literature review of case reports/series of MDs as irAEs of ICIs was performed.

Results

Of 5682 eligible papers, 26 articles with 28 patients were included. MDs occur as a rare complication of cancer immunotherapy with heterogeneous clinical presentations and in most cases in association with other irAEs. Inflammatory basal ganglia T2/fluid attenuated inversion recovery abnormalities are rarely observed, but brain imaging is frequently unrevealing. Cerebrospinal fluid findings are frequently suggestive of inflammation. Half of cases are associated with a wide range of autoantibodies. Steroids and ICI withdrawal usually lead to improvement, even though some patients experienced relapses or a severe clinical course.

Conclusion

MDs are a rare complication of ICIs that should be promptly recognized to offer patients a correct diagnosis and treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsMovement DisordersHumansAutoimmune DiseasesImmunotherapyNeoplasms

Stichwörter der Autor:innen

autoimmune movement disordersimmune checkpoint inhibitorsimmune‐related adverse eventsparaneoplastic neurological syndrome

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Neurology Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

ORCID-Profile: Alessandro Dinoto, Stefano Tamburin, Michele Tinazzi, Sara Mariotto

Zitieren

APA

Dinoto, A., Trentinaglia, M., Carta, S., Mantovani, E., Ferrari, S., Tamburin, S., Tinazzi, M., & Mariotto, S. (2024). Autoimmune Movement Disorders Complicating Treatment with Immune Checkpoint Inhibitors. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.14003

Vancouver

Dinoto A, Trentinaglia M, Carta S, Mantovani E, Ferrari S, Tamburin S, et al. Autoimmune Movement Disorders Complicating Treatment with Immune Checkpoint Inhibitors. Movement Disorders Clinical Practice. 2024. doi:10.1002/mdc3.14003

BibTeX
@article{Dinoto2024,
  author = {Dinoto, Alessandro and Trentinaglia, Milena and Carta, Sara and Mantovani, Elisa and Ferrari, Sergio and Tamburin, Stefano and Tinazzi, Michele and Mariotto, Sara},
  title = {Autoimmune Movement Disorders Complicating Treatment with Immune Checkpoint Inhibitors},
  journal = {Movement Disorders Clinical Practice},
  year = {2024},
  doi = {10.1002/mdc3.14003}
}
Kostenlos starten →